Sugi Predict

Sugi Predict / Compounds / SCHEMBL896714

SCHEMBL896714

SCHEMBL896714

CCOC(=O)C(C(=O)OCC)c1ncccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ TSHR P16473 1/20 0.45
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ GAA P10253 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ CYP2C19 P33261 2/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ S1PR3 Q99500 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487291 0.96 ALDH1A1 (0.53) ALDH1A1TSHRKMT2AMEN1GAA
SCHEMBL2692083 0.86 TSHR (0.47) ALDH1A1TSHRKMT2AMEN1GAA
SCHEMBL28049801 0.85 KMT2A (0.43) ALDH1A1KMT2AMEN1GAASMN1; SMN2
SCHEMBL4924785 0.84 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1GAASMN1; SMN2
SCHEMBL896383 0.81 ALDH1A1 (0.50) ALDH1A1TSHRKMT2AMEN1GAA
SCHEMBL931530 0.80 ALDH1A1 (0.49) ALDH1A1TSHRKMT2AMEN1GAA
SCHEMBL896254 0.79 MEN1 (0.41) ALDH1A1TSHRKMT2AMEN1GAA
SCHEMBL16352668 0.78 S1PR3 (0.41) ALDH1A1KMT2AMEN1GAASMN1; SMN2
SCHEMBL895488 0.78 ALDH1A1 (0.44) ALDH1A1TSHRKMT2AMEN1GAA
SCHEMBL29392267 0.77 ALDH1A1 (0.80) ALDH1A1GAASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORP (US) 2025-09-11 — — US disclosed
CN-113166153-B Fused pyrazine derivatives as A2A/A2B inhibitors 因赛特公司 2024-11-01 — — CN disclosed
US-20240360140-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2024-10-31 — — US disclosed
EP-4448526-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2024-10-23 — — EP disclosed
US-11999740-B2 Fused pyrazine derivatives as A2A / A2B inhibitors INCYTE CORPORATION (US) 2024-06-04 — — US disclosed
CN-117304191-A Fused pyrazine derivatives as A2A/A2B inhibitors 因赛特公司 2023-12-29 — — CN disclosed
EP-4227307-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Genzyme Corporation (US) 2023-08-16 — — EP disclosed
WO-2023114954-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2023-06-22 — — WO disclosed
EP-3174877-B1 INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2022-06-29 — — EP disclosed
EP-3174877-B1 INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2022-06-29 — — EP disclosed
US-8258136-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-04 — — US disclosed
CN-101326176-B Pyridazine compound and use thereof SUMITOMO CHEMICAL CO 2012-05-30 — — CN disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 — — US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 — — US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 — — US disclosed
EP-1958946-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-02-23 — — EP disclosed
EP-1958946-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-02-23 — — EP disclosed
US-20090275589-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-05 — — US disclosed
CN-101326176-A Pyridazine compound and use thereof SUMITOMO CHEMICAL CO (JP) 2008-12-17 — — CN disclosed
EP-1958946-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360140-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885TSHR 379/4885KMT2A 2407/4885
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS PTPN5, PTPN2, PTPRJ ALDH1A1 3844/4885TSHR 2223/4885KMT2A 1435/4885
US-11999740-B2 Fused pyrazine derivatives as A2A / A2B inhibitors ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885TSHR 379/4885KMT2A 2407/4885
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF PLPBP, PNPO, PDXK ALDH1A1 3397/4885TSHR 2386/4885KMT2A 1894/4885
US-20090275589-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK ALDH1A1 3397/4885TSHR 2386/4885KMT2A 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.